NDC 63323-286-01 - NAROPIN
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 63323-286
- Requested NDC
- 63323-286-01
- Package NDCs from labels
- 63323-286-51, 63323-286-55, 63323-286-41, 63323-286-27, 63323-286-43, 63323-286-38, 63323-286-01, 63323-286-20, 63323-286-05, 63323-286-23, 63323-286-09, 63323-286-31, 63323-286-11, 63323-286-35, 63323-286-03, 63323-286-00, 63323-286-33, 63323-286-63, 63323-286-30, 63323-286-93, 63323-286-95
- Manufacturer
- Henry Schein, Inc.
- Effective date
- 2026-07-22
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| NAROPIN - Henry Schein, Inc. | Henry Schein, Inc. | 2026-07-22 | HUMAN PRESCRIPTION DRUG LABEL |
| Naropin - Fresenius Kabi USA, LLC | Fresenius Kabi USA, LLC | 2026-07-17 | HUMAN PRESCRIPTION DRUG LABEL |
| Naropin - Fresenius Kabi USA, LLC | Fresenius Kabi USA, LLC | 2024-08-15 | HUMAN PRESCRIPTION DRUG LABEL |
| Naropin - Fresenius Kabi USA, LLC | Fresenius Kabi Austria | HP Halden Pharma AS | Fresenius Kabi USA, LLC | Fresenius Kabi Austria | HP Halden Pharma AS | 2024-08-06 | HUMAN PRESCRIPTION DRUG LABEL |
| Naropin - Fresenius Kabi USA, LLC | Fresenius Kabi USA, LLC | 2024-07-10 | HUMAN PRESCRIPTION DRUG LABEL |
| NAROPIN - General Injectables & Vaccines, Inc | General Injectables & Vaccines, Inc | 2022-12-29 | HUMAN PRESCRIPTION DRUG LABEL |
| Naropin - APP Pharmaceuticals, LLC | Fresenius Kabi Norge AS | APP Pharmaceuticals, LLC | Fresenius Kabi Norge AS | 2011-09-15 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 63323-286-00 | Naropin | 12 in 1 CASE | INJECTION, SOLUTION | 12 | 27 | |
| 63323-286-01 | Naropin | 20 mL in 1 AMPULE | INJECTION, SOLUTION | 20 | 27 | |
| 63323-286-03 | Naropin | 100 mL in 1 BOTTLE | INJECTION, SOLUTION | 100 | 27 | |
| 63323-286-05 | Naropin | 20 mL in 1 VIAL, SINGLE-DOSE | INJECTION, SOLUTION | 20 | 27 | |
| 63323-286-09 | Naropin | 30 mL in 1 VIAL, SINGLE-DOSE | INJECTION, SOLUTION | 30 | 27 | |
| 63323-286-11 | Naropin | 30 mL in 1 VIAL, SINGLE-DOSE | INJECTION, SOLUTION | 30 | 27 | |
| 63323-286-20 | Naropin | 5 in 1 BOX | INJECTION, SOLUTION | 5 | 27 | |
| 63323-286-23 | Naropin | 25 in 1 CARTON | INJECTION, SOLUTION | 25 | 27 | |
| 63323-286-30 | Naropin | 30 mL in 1 VIAL, SINGLE-DOSE | INJECTION, SOLUTION | 30 | 27 | |
| 63323-286-30 | Naropin | 1 in 1 BOX | INJECTION, SOLUTION | 1 | 27 | |
| 63323-286-31 | Naropin | 5 in 1 BOX | INJECTION, SOLUTION | 5 | 27 | |
| 63323-286-33 | Naropin | 200 mL in 1 BOTTLE | INJECTION, SOLUTION | 200 | 27 | |
| 63323-286-35 | Naropin | 25 in 1 CARTON | INJECTION, SOLUTION | 25 | 27 | |
| 63323-286-63 | Naropin | 12 in 1 CASE | INJECTION, SOLUTION | 12 | 27 | |
| 63323-286-93 | Naropin | 30 mL in 1 VIAL, SINGLE-DOSE | INJECTION, SOLUTION | 30 | 8 | |
| 63323-286-95 | Naropin | 25 in 1 TRAY | INJECTION, SOLUTION | 25 | 8 | |
| 63323-286-27 | Naropin | 25 in 1 CARTON | INJECTION, SOLUTION | 25 | 6 | |
| 63323-286-38 | Naropin | 25 in 1 CARTON | INJECTION, SOLUTION | 25 | 6 | |
| 63323-286-41 | Naropin | 20 mL in 1 VIAL, SINGLE-DOSE | INJECTION, SOLUTION | 20 | 6 | |
| 63323-286-43 | Naropin | 30 mL in 1 VIAL, SINGLE-DOSE | INJECTION, SOLUTION | 30 | 6 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 63323-286 | NAROPIN (ROPIVACAINE HYDROCHLORIDE) INJECTION, SOLUTION [FRESENIUS KABI USA, LLC ] | 27 | Current NDC, Legacy NDC, 14 package rows | 20240814_23d2d448-a744-4877-9f2d-7e57c198da89.zip |
| 63323-286 | NAROPIN (ROPIVACAINE HYDROCHLORIDE) INJECTION, SOLUTION [FRESENIUS KABI USA, LLC ] | 8 | Current NDC, Legacy NDC, 2 package rows | 20240817_c6613708-c1f7-4f5c-91a3-ebbc1d7905c6.zip |
| 63323-286 | NAROPIN (ROPIVACAINE HYDROCHLORIDE) INJECTION, SOLUTION [FRESENIUS KABI USA, LLC ] | 6 | Current NDC, Legacy NDC, 4 package rows | 20240829_dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7.zip |
DailyMed Billing Units#
DailyMed Socrata Ingredients#
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Sodium Chloride | SODIUM CHLORIDE | Baxter Healthcare Corporation | 2a96096d-43cc-49b7-af53-b53c17f41001 | 2014-07-25 | Warnings, Adverse reactions | 451W47IQ8X |
| SODIUM CHLORIDE | SODIUM CHLORIDE | Baxter Healthcare Corporation | b3b4b176-41f0-4ca8-90d4-3fba5707564a | 2014-02-21 | 451W47IQ8X | |
| TIS-U-SOL | SODIUM CHLORIDE, POTASSIUM CHLORIDE, MAGNESIUM SULFATE, SODIUM PHOSPHATE, AND POTASSIUM PHOSPHATE | Baxter Healthcare Corporation | 9da4121f-d62d-4da4-8dfb-0494da16015f | 2014-02-21 | 451W47IQ8X | |
| Ringers | SODIUM CHLORIDE, CALCIUM CHLORIDE, POTASSIUM CHLORIDE, | Baxter Healthcare Corporation | e1953d54-818d-46a6-8532-518ebae6d84e | 2012-06-13 | 451W47IQ8X | |
| Lactated Ringers | SODIUM CHLORIDE, SODIUM LACTATE, POTASSIUM CHLORIDE, CALCIUM CHLORIDE | Baxter Healthcare Corporation | f09f80bf-2f8b-4420-865d-aec2d5e5cd4d | 2012-06-12 | 451W47IQ8X | |
| c5a1ce28-2785-45e2-ad20-32dd83b626ea | f27790b5-cdb9-4fd2-b575-70686a5cbb58 | 2011-09-15 | Warnings, Adverse reactions | c5a1ce28-2785-45e2-ad20-32dd83b626ea f27790b5-cdb9-4fd2-b575-70686a5cbb58 |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.